While Trump has been wildly inconsistent on his plans for reciprocal tariffs, levies on imported pharmaceuticals appear to be ...

Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood product specialist remains hopeful that Hemgenix is here to stay. “I hope ...

The fourth beaten-down stock with an apparent price dislocation that I bought during Wall Street's historic volatility is ...

The U.S. does not buy drugs directly for a national health system, as countries such as England and Germany do, instead ...

U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that ...

The pharma sector had been spared last week from Trump's sweeping tariff plan, which kicked in Wednesday, and drug companies have been exempt from trade taxes for decades. But Trump has previously ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Goldman Sachs made significant rating changes across its U.S. biopharma coverage on Tuesday, upgrading the likes of Eli Lilly ...

Pfizer's abnormally high yield seems more a symptom of all this negative sentiment than a red flag about the dividend's sustainability. Management just raised the quarterly dividend in December, and ...